Visit COVID-19 resources

[Skip to Content]

licensing

Response to SMC Decision to accept Eylea for wet AMD

Statement from The Royal College of Ophthalmologists The Royal College of Ophthalmologists welcomes the SMC decision to recommend Aflibercept (Eylea®) as a treatment for neovascular AMD. Aflibercept is a soluble vascular endothelial growth factor (VEGF) receptor fusion protein which binds to all forms of VEGF and inhibits its actions. This drug has been shown in